720 related articles for article (PubMed ID: 26777991)
1. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
2. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
3. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
5. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
[TBL] [Abstract][Full Text] [Related]
6. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
[TBL] [Abstract][Full Text] [Related]
8. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.
Lim MC; Yoo HJ; Song YJ; Seo SS; Kang S; Kim SH; Yoo CW; Park SY
J Gynecol Oncol; 2017 Jul; 28(4):e48. PubMed ID: 28541636
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
Mueller JJ; Kelly A; Zhou Q; Iasonos A; Long Roche K; Sonoda Y; O'Cearbhaill RE; Zivanovic O; Chi DS; Gardner GJ
Gynecol Oncol; 2016 Dec; 143(3):496-503. PubMed ID: 27692668
[TBL] [Abstract][Full Text] [Related]
12. [Advanced ovarian cancer: primary debulking (PDS) or neoadjuvant chemotherapy (NACT) - still a debate].
Segev Y; Gemer O; Auslender R; Lavie O
Harefuah; 2014 Sep; 153(9):527-31, 558. PubMed ID: 25417489
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.
Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Morrison J; Haldar K; Kehoe S; Lawrie TA
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD005343. PubMed ID: 22895947
[TBL] [Abstract][Full Text] [Related]
15. What is the optimal treatment for obese patients with advanced ovarian carcinoma?
Worley MJ; Guseh SH; Rauh-Hain JA; Esselen KM; Muto MG; Feltmate CM; Berkowitz RS; Del Carmen MG; Schorge JO; Horowitz NS
Am J Obstet Gynecol; 2014 Sep; 211(3):231.e1-9. PubMed ID: 24704062
[TBL] [Abstract][Full Text] [Related]
16. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
Seagle BL; Graves S; Strohl AE; Shahabi S
Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer.
Kessous R; Laskov I; Abitbol J; Bitharas J; Yasmeen A; Salvador S; Lau S; Gotlieb WH
Gynecol Oncol; 2017 Mar; 144(3):474-479. PubMed ID: 28041690
[TBL] [Abstract][Full Text] [Related]
18. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
Chishti U; Aziz AB
J Pak Med Assoc; 2015 Mar; 65(3):306-9. PubMed ID: 25933567
[TBL] [Abstract][Full Text] [Related]
19. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
[TBL] [Abstract][Full Text] [Related]
20. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
